154323-57-6 Categories: , ,
  • #LGM Pharma is a Almotriptan CAS# 154323-57-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 154323-57-6
  • AHFC code:
  • Synonyms: 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine, Almotriptan, LAS 31416, UNII-1O4XL5SN61
  • ATC Code: N02CC05
  • Chemical Formula: C17-H25-N3-O2-S
  • Molecular Weight: 335.47
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00918
  • SMILES: c1c(cc2c(c[nH]c2c1)CCN(C)C)CS(N1CCCC1)(=O)=O
  • InChl: 1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
  • PubChem: 123606
  • IUPAC: N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine

Additional Details

Almotriptan is specifically indicated for the treatment of migraine headaches, with or without aura in both adults and adolescents ages twelve to seventeen. Patients who have a history of migraines, with or without aura, which last an average of four hours or longer are candidates for therapy with Almotriptan. Prophylactic therapy and treatment of cluster headaches are not indicated for Almotriptan therapy.
The therapeutic efficacy of Almotriptan is thought to be attributed to agonist effects at 5-HT1B/1D receptors. An activation of these receptors aids in cranial vessel constriction, reduced transmission in the trigeminal pain pathways and an inhibition of neuropeptide releases.
Mode of Action:
Almotriptan bonds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors, and has an absolute bioavailability of approximately 70 percent. Peak plasma levels of Almotriptan occur roughly 1 to 3 hours after administration.
Almotriptan is metabolized by major pathways monoamine oxidase-mediated oxidative deamination and cytochrome P450-mediated oxidation. Renal excretion of Almotriptan is primary, about 70 percent of the dosage, with roughly 40 percent of an administered dose excreted unchanged in urine.
Patients with severe renal impairment or who have ischemic heart disease should not be administered Almotriptan. In patients with hepatic impairment the recommended starting dose of Almotriptan is 6.25 milligrams, not exceeding 12.5 milligrams in a 24 hour period. Typical side effects include reports of dizziness, nausea, tiredness and dry mouth.
General Reference:
Neurol Sci. 2014 May;35 Suppl 1:115-9. doi: 10.1007/s10072-014-1752-2.Headache: The Journal of Head and Face Pain. Multiple years/issues.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials